SETD2 and neoplasm: Malignant peritoneal mesothelioma is a rare tumor with limited treatment 92,97, gene sequencing of 13 patients with malignant mesothelioma has shown SETD2 mutation in malignant peritoneal mesothelioma, and it may be linked to PI3K-mTOR signaling pathway, which is expected to become a new target for the treatment of this type of tumor 92,97 (Table 2).